Trial Profile
An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 13 Apr 2021 Status changed from active, no longer recruiting to completed.
- 07 Mar 2021 This trial has been completed in Netherlands, according to European Clinical Trials Database record. (Global end date: 2021-01-28)
- 01 Mar 2021 This trial has been completed in as per Belgium global end of the trial (2021-01-28) European Clinical Trials Database record.